Nurix Therapeutics, Inc. (NRIX) Key Metrics
NRIX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.67B
- Enterprise value
- $2.09B
- P/E (TTM)
- 10.0
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 3.8 10-yr median 18.2
- Price / book
- 6.2 10-yr median 2.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.82
NRIX key metrics, FY2018–FY2025
Fiscal year ended November 30, 2025 · U.S. dollarsNRIX valuation Price multiples at each fiscal year-end price.
NRIX returns How much profit the business earns on the capital it uses.
NRIX per-share figures Results divided by the shares outstanding at year-end.
NRIX financial health Debt, liquidity and how easily interest is covered.
NRIX efficiency & capital use Working capital cycle and where the cash goes.
NRIX valuation history
NRIX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NRIX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NRIX cash returned to shareholders
NRIX price vs earnings per share
NRIX key metrics
FY2018–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $1.53B | $1.48B | $338.0M | $602.3M | $1.24B | — | — | — |
| Enterprise value | $995.1M | $902.7M | $80.7M | $305.1M | $953.6M | — | — | — |
| Price / sales | 18.2 | 27.2 | 4.4 | 15.6 | 41.6 | — | — | — |
| Price / book | 2.8 | 2.8 | 1.7 | 2.0 | 3.6 | — | — | — |
| EV / sales | 11.8 | 16.5 | 1.0 | 7.9 | 32.1 | — | — | — |
| Earnings yield | −17.3% | −13.0% | −42.6% | −27.6% | −9.5% | — | — | — |
| Free cash flow yield | −17.2% | −12.3% | −26.6% | −28.6% | −7.3% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | — | — | — |
| Share price at fiscal year-end | $17.68 | $22.11 | $6.22 | $12.39 | $28.82 | $42.62 | — | — |
| Per share | ||||||||
| Revenue per share | $0.97 | $0.81 | $1.42 | $0.79 | $0.69 | — | $0.80 | — |
| Earnings per share | −$3.05 | −$2.88 | −$2.65 | −$3.42 | −$2.73 | — | −$0.56 | — |
| Operating cash flow per share | −$2.88 | −$2.57 | −$1.50 | −$3.29 | −$1.97 | — | $0.02 | — |
| Free cash flow per share | −$3.04 | −$2.71 | −$1.65 | −$3.54 | −$2.10 | — | −$0.03 | — |
| Cash per share | $6.84 | $9.08 | $5.30 | $6.36 | $6.89 | — | $0.97 | — |
| Book value per share | $6.22 | $7.85 | $3.69 | $6.25 | $7.98 | — | −$1.49 | — |
| Tangible book value per share | $6.22 | $7.85 | $3.69 | $6.25 | $7.98 | — | −$1.49 | — |
| Capex per share | $0.16 | $0.14 | $0.15 | $0.25 | $0.13 | — | $0.04 | — |
| Debt per share | $0.64 | $0.42 | $0.56 | $0.25 | $0.30 | — | $0.12 | — |
| Shares outstanding | 86.7M | 67.1M | 54.3M | 48.6M | 42.9M | — | 38.8M | — |
| Change in shares outstanding | +29.1% | +23.5% | +11.8% | +13.3% | — | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −49.6% | −53.2% | −57.1% | −51.4% | −37.1% | −37.2% | — | — |
| Return on invested capital (ROIC) | — | — | — | −439.3% | −243.9% | — | — | — |
| Return on assets (ROA) | −39.0% | −37.8% | −37.3% | −37.2% | −26.8% | −19.6% | −48.5% | −20.8% |
| Return on tangible assets | −38.4% | −28.9% | −40.5% | −39.8% | −24.6% | −10.9% | −49.3% | −20.8% |
| Free cash flow margin | −313.7% | −333.4% | −116.6% | −445.4% | −302.6% | −26.0% | −3.4% | −88.8% |
| Financial health | ||||||||
| Total debt | $55.7M | $28.3M | $30.6M | $12.0M | $13.0M | $7.6M | $4.6M | $2.8M |
| Cash & short-term investments | $592.9M | $609.6M | $287.9M | $309.1M | $295.7M | $281.1M | $37.7M | $39.0M |
| Net debt | −$537.2M | −$581.3M | −$257.3M | −$297.2M | −$282.7M | −$273.5M | −$33.1M | −$36.2M |
| Debt / equity | 0.10 | 0.05 | 0.15 | 0.04 | 0.04 | 0.03 | — | — |
| Debt / assets | 0.08 | 0.04 | 0.09 | 0.03 | 0.03 | 0.02 | 0.10 | 0.06 |
| Current ratio | 7.02 | 6.46 | 3.40 | 4.51 | 4.70 | 6.70 | 2.44 | 1.24 |
| Quick ratio | 7.02 | 6.46 | 3.40 | 4.52 | 4.70 | 6.70 | 2.44 | 1.24 |
| Interest coverage | — | — | — | -12.8 | -17.1 | -19.2 | -28.7 | -11.9 |
| Working capital | $520.3M | $523.5M | $208.5M | $247.8M | $244.9M | $253.9M | $23.2M | $7.8M |
| Invested capital | $1.5M | −$54.3M | −$56.8M | $6.5M | $59.6M | $16.7M | −$90.8M | −$73.0M |
| Tangible asset value | $538.7M | $527.0M | $200.5M | $303.7M | $342.3M | $290.3M | −$9.5M | $11.3M |
| Net current asset value | $457.4M | $477.0M | $140.4M | $205.4M | $176.6M | $192.4M | −$14.2M | $6.6M |
| Graham net-net per share | $5.12 | $6.98 | $2.46 | $4.04 | $3.87 | — | −$0.41 | — |
| Capital allocation | ||||||||
| Share buybacks (net) | — | — | — | $0 | $1,000 | $7,000 | $16,000 | $2,000 |
| Capex / revenue | 16.7% | 17.0% | 10.9% | 31.7% | 19.0% | 25.5% | 5.3% | 4.3% |
| Capex / operating cash flow | — | — | — | — | — | — | 274.7% | — |
| Capex / depreciation | 0.74 | 0.56 | 0.62 | 1.13 | 0.93 | 2.09 | 0.70 | 0.53 |
| Stock-based compensation / revenue | 45.2% | 62.2% | 43.7% | 72.8% | 53.1% | 24.1% | 1.6% | 1.2% |
| R&D / revenue | 366.9% | 406.3% | 245.7% | 477.6% | 391.4% | 373.1% | 144.7% | 108.2% |
| SG&A / revenue | 62.8% | 84.2% | 55.7% | 98.4% | 104.9% | 91.5% | 26.8% | 17.8% |
| Efficiency | ||||||||
| Days sales outstanding | — | 7.7 | 4.5 | 34.5 | 107.7 | 232.4 | — | — |
| Days of inventory on hand | — | — | — | -18.6 | 0.0 | — | — | — |
| Days payables outstanding | 219.7 | 14.7 | 11.1 | 197.8 | 301.9 | 13.8 | 11.7 | 11.7 |
| Cash conversion cycle (days) | — | -7.0 | -6.6 | -181.9 | -194.3 | 218.6 | — | — |
| Receivables turnover | — | 47.43 | 81.04 | 10.58 | 3.39 | 1.57 | — | — |
| Payables turnover | 1.66 | 24.79 | 33.00 | 1.85 | 1.21 | 26.54 | 31.11 | 31.24 |
| Inventory turnover | — | — | — | — | 6,082,000.00 | — | — | — |
| Asset turnover | 0.12 | 0.11 | 0.20 | 0.09 | 0.07 | 0.08 | 0.70 | 0.82 |
| Average receivables | — | $1.1M | $950,000 | $3.7M | $8.8M | $11.3M | — | — |
| Average payables | $11.3M | $8.9M | $5.7M | $5.9M | $5.0M | $2.5M | $1.4M | $1.3M |
| Average inventory | — | — | — | −$550,000 | $1 | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from NRIX's annual financial statements (latest annual report filed January 28, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NRIX valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 10.0. Nurix Therapeutics earned a return on equity of −49.6% in fiscal 2025. It ended the year with $55.7 million of debt and $592.9 million in cash and short-term investments, a net cash position of $537.2 million.
See the NRIX income statement, the NRIX chart for price history, or the NRIX stock overview for the latest quote and news.
NRIX key metrics FAQ
What is Nurix Therapeutics's P/E ratio?
Nurix Therapeutics's trailing P/E ratio is 10.0 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was —.
What is Nurix Therapeutics's return on equity?
Nurix Therapeutics's return on equity (ROE) was −49.6% in fiscal 2025: net income of -$264.5 million on average shareholders' equity of $532.9 million.
How much debt does Nurix Therapeutics have?
Nurix Therapeutics had total debt of $55.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.10 and more cash than debt.
What is Nurix Therapeutics's free cash flow yield?
Nurix Therapeutics generated -$263.5 million of free cash flow in fiscal 2025, a free cash flow yield of −17.2% on its market value at year-end ($1.5 billion).
What is Nurix Therapeutics's current ratio?
Nurix Therapeutics's current ratio was 7.02 at the end of fiscal 2025: current assets were 7.02 times current liabilities.